UCB’s IL-17 latecomer bimekizumab beats Cosentyx in psoriasi...

Belgian biopharma company UCB is bringing up the rear of the IL-17 inhibitor category with its bimekizumab drug, so is celebrating new late-stage data showing superiority to th

Lilly’s mirikizumab tops Novartis’ blockbuster Cosentyx in p...

Eli Lilly is a latecomer in the new generation of biologic therapies for psoriasis with its mirikizumab candidate, but a win in a head-to-head trial against Novartis’ big-selli

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

Amid tough competition, Novartis makes case for rheumatology...

Swiss pharma hopes to bounce back from Q1 sales disappointment

Novartis trumpets long-term data for Cosentyx in psoriasis

Novartis is hoping that new real world data will help its psoriasis drug Cosentyx stay ahead of rivals.

Imbruvica, Opdivo and Praluent gain approvals for Scotland’s...

Sanofi steals a march on rivals Amgen